# ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

> **NCT01478074** · PHASE1 · WITHDRAWN · sponsor: **Altor BioScience**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** G-CSF
- **DRUG:** Cytarabine
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Donor Natural Killer (NK) cells
- **BIOLOGICAL:** ALT-801

## Key facts

- **NCT ID:** NCT01478074
- **Lead sponsor:** Altor BioScience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-11
- **Primary completion:** 2013-10
- **Final completion:** 2013-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The treatment planned was determined to be of low feasibility as no subject was found eligible and able to enroll after screening over 30 subjects
- **Last updated:** 2014-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01478074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01478074, "ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01478074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*